| Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution E Caronna, A Ballvé, A Llauradó, VJ Gallardo, DM Ariton, S Lallana, ... Cephalalgia 40 (13), 1410-1421, 2020 | 223 | 2020 |
| When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month M Torres-Ferrús, M Quintana, J Fernandez-Morales, J Alvarez-Sabin, ... Cephalalgia 37 (2), 104-113, 2017 | 97 | 2017 |
| From transformation to chronification of migraine: pathophysiological and clinical aspects M Torres-Ferrús, F Ursitti, A Alpuente, F Brunello, D Chiappino, T de Vries, ... The journal of headache and pain 21, 1-12, 2020 | 86 | 2020 |
| OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study C Domínguez, P Pozo‐Rosich, M Torres‐Ferrús, N Hernández‐Beltrán, ... European Journal of Neurology 25 (2), 411-416, 2018 | 79 | 2018 |
| Headache, comorbidities and lifestyle in an adolescent population (The TEENs Study) M Torres-Ferrus, C Vila-Sala, M Quintana, S Ajanovic, VJ Gallardo, ... Cephalalgia 39 (1), 91-99, 2019 | 72 | 2019 |
| Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months E Caronna, VJ Gallardo, A Alpuente, M Torres-Ferrus, P Pozo-Rosich The journal of headache and pain 22, 1-7, 2021 | 62 | 2021 |
| The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study M Torres-Ferrús, VJ Gallardo, A Alpuente, E Caronna, E Gine-Cipres, ... Journal of Neurology, 1-10, 2021 | 60 | 2021 |
| Toward a better understanding of persistent headache after mild COVID‐19: three migraine‐like yet distinct scenarios E Caronna, A Alpuente, M Torres‐Ferrus, P Pozo‐Rosich Headache: The Journal of Head and Face Pain 61 (8), 1277-1280, 2021 | 49 | 2021 |
| Salivary CGRP can monitor the different migraine phases: CGRP (in) dependent attacks A Alpuente, VJ Gallardo, L Asskour, E Caronna, M Torres-Ferrus, ... Cephalalgia 42 (3), 186-196, 2022 | 38 | 2022 |
| MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention R Belvís, P Irimia, P Pozo-Rosich, C González-Oria, A Cano, J Viguera, ... The Journal of Headache and Pain 22, 1-8, 2021 | 35 | 2021 |
| Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA M Torres-Ferrus, VJ Gallardo, A Alpuente, P Pozo-Rosich The journal of headache and pain 21, 1-8, 2020 | 31 | 2020 |
| Salivary CGRP and erenumab treatment response: towards precision medicine in migraine A Alpuente, VJ Gallardo, L Asskour, E Caronna, M Torres‐Ferrus, ... Annals of Neurology 92 (5), 846-859, 2022 | 30 | 2022 |
| Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications E Caronna, VJ Gallardo, A Alpuente, M Torres-Ferrus, ... Neurologia 36 (8), 611-617, 2021 | 29 | 2021 |
| In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study A Alpuente, VJ Gallardo, E Caronna, M Torres-Ferrus, P Pozo-Rosich The Journal of Headache and Pain 22, 1-10, 2021 | 24 | 2021 |
| Early efficacy and late gain in chronic and high‐frequency episodic migraine with onabotulinumtoxinA A Alpuente, VJ Gallardo, M Torres‐Ferrus, J Alvarez‐Sabin, ... European Journal of Neurology 26 (12), 1464-1470, 2019 | 23 | 2019 |
| How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? a patient's perspective M Torres-Ferrus, A Alpuente, P Pozo-Rosich Current Opinion in Neurology 32 (3), 395-404, 2019 | 22 | 2019 |
| Aetiology and treatment of epilepsy in a series of 1,557 patients M Torres-Ferrús, M Toledo, M González-Cuevas, L Seró-Ballesteros, ... Revista de Neurologia 57 (7), 306-312, 2013 | 22 | 2013 |
| Partial and nonresponders to onabotulinumtoxinA can benefit from anti‐CGRP Monoclonal antibodies preventive treatment: a real‐world evidence study A Alpuente, VJ Gallardo, E Caronna, M Torres‐Ferrús, P Pozo‐Rosich European Journal of Neurology 28 (7), 2378-2382, 2021 | 21 | 2021 |
| How and when to refer patients diagnosed with primary headache and craniofacial neuralgia in the emergency department or primary care: recommendations of the Spanish Society of … AB Gago-Veiga, D García-Azorín, N Mas-Sala, CM Ordás, M Ruiz-Piñero, ... Neurología (English Edition) 35 (3), 176-184, 2020 | 16 | 2020 |
| Short and mid‐term predictors of response to onabotulinumtoxina: Real‐life experience observational study A Alpuente, VJ Gallardo, M Torres‐Ferrús, J Álvarez‐Sabin, ... Headache: The Journal of Head and Face Pain 60 (4), 677-685, 2020 | 16 | 2020 |
